Merck held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3bn

MSD rumoured to be eyeing $3bn+ MoonLake takeover

Faced with the looming loss of patent protection for Keytruda, MSD is reported to be interested in buying Swiss immunology player MoonLake

Biotech Stock Catapults On Rumored Merck Takeover

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion."

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report - MoonLake (NASDAQ:MLTX), Merck & Co (NYSE:MRK)

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer, talks may be revived. The potential deal signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster cancer drug Keytruda faces patent expiration as early as 2028. MoonLake Immunothe…

Merck Held Talks to Buy Biotech MoonLake for Over $3 Billion, FT Reports

Merck & Co., Inc. (MRK) Held Talks Over $3 Billion Acquisition of Swiss ...

Merck held talks to buy Swiss biotech MoonLake for more than $3bn

Merck has held talks over a more than $3bn acquisition of Swiss biotechnology group MoonLake Immunotherapeutics, as the US pharmaceutical company seeks to replenish its drug pipeline. The New Jersey-based drugmaker submitted a nonbinding offer for MoonLake earlier this year, valuing the business in excess of $3bn, a premium to its $2.6bn market value, according […] The post Merck held talks to buy Swiss biotech MoonLake for more than $3bn appear…